-
NBD-556
- names:
NBD-556
- CAS号:
333353-44-9
MDL Number: MFCD00469538 - MF(分子式): C17H24ClN3O2 MW(分子量): 337.84
- EINECS:No data available Reaxys Number:No data available
- Pubchem ID:1570601 Brand:BIOFOUNT
货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
---|---|---|---|---|---|---|---|---|
YZM000666-10mg | 10mg | 99.58% | ¥ 1129.00 | ¥ 1129.00 | 2-3天 | ¥ 0.00 | ||
YZM000666-5mg | 5mg | 99.58% | ¥ 580.13 | ¥ 580.13 | 2-3天 | ¥ 0.00 |
中文别名 | NBD-556(333353-44-9);NBD 556;NBD-556;NBD556;N-(4-氯苯基)-N'-(2,2,6,6-四甲基哌啶-4-基)草酰胺; |
英文别名 | NBD-556(333353-44-9);NBD 556;NBD-556;NBD556;N-(4-chlorophenyl)-N'-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide |
CAS号 | 333353-44-9 |
SMILES | O=C(C(NC1CC(C)(NC(C)(C1)C)C)=O)NC2=CC=C(C=C2)Cl |
Inchi | InChI=1S/C17H24ClN3O2/c1-16(2)9-13(10-17(3,4)21-16)20-15(23)14(22)19-12-7-5-11(18)6-8-12/h5-8,13,21H,9-10H2,1-4H3,(H,19,22)(H,20,23) |
InchiKey | ZKXLQCIOURANAD-UHFFFAOYSA-N |
分子式 Formula | C17H24ClN3O2 |
分子量 Molecular Weight | 337.84 |
闪点 FP | No data available |
熔点 Melting point | No data available |
沸点 Boiling point | No data available |
Polarizability极化度 | 36.3±0.5 10-24cm3 |
密度 Density | 1.2±0.1 g/cm3 |
蒸汽压 Vapor Pressure | No data available |
溶解度Solubility | 生物体外In Vitro:DMSO溶解度33.33 mg/mL(98.66 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble) |
性状 | 白色至米色固体粉末,Power |
储藏条件 Storage conditions | 2-8°C°, 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
NBD-556(333353-44-9)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:NBD-556试剂,NBD-556杂质,NBD-556中间体,NBD-556密度,NBD-556旋光度,NBD-556溶解度,NBD-556闪点,NBD-556熔点,NBD-556购买,NBD-556结构式,
产品说明 | NBD-556(333353-44-9)是CD4的小分子模拟物,能识别HIV-1包膜蛋白gp120。 |
Introduction | NBD56(333353-44-9) is small molecule mimetic of CD4, NBD56 recognizes the HIV envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.IC50 Value: |
Application1 | NBD-556是一种N-苯基-N'-(2,2,6,6-四甲基哌啶-4-基)-草酰胺类似物,是一类新型的人类免疫缺陷病毒1型(HIV-1)进入抑制剂, 阻止gp120-CD4相互作用。 |
Application2 | NBD-556 is a N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analog, a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction. |
Application3 |
NBD-556(333353-44-9)药理学:
※NBD-556是CD4的小分子模拟物,NBD-556识别HIV-1包膜蛋白gp120,并诱导gp120的重组,类似于CD4结合。IC50值:目标人群:HIV NBD-556 N-苯基-N'-(2,2,6,6-四甲基哌啶-4-基)-草酰胺类似物,是新型的1类人类免疫缺陷病毒(HIV-1 )可阻止gp120-CD4相互作用的进入抑制剂。人免疫缺陷病毒(HIV-1)与主要受体CD4的相互作用会诱导病毒包膜糖蛋白的构象变化,从而使蛋白与CCR5第二受体结合,并使病毒进入宿主细胞。小分子NBD-556通过结合gp120外膜糖蛋白来模拟CD4。
※NBD-556是CD4模拟物(IC50值在低微摩尔范围内,取决于细胞类型和HIV株)。识别并诱导HIV-1包膜蛋白gp120中的结构变化,类似于CD4结合。通过阻止病毒细胞和细胞-细胞融合,抑制HIV-1细胞进入CXCR4和CCR5表达细胞系。
※NBD-556是CD4的小分子模拟物,NBD-556识别HIV-1包膜蛋白gp120并诱导gp120的重组,类似于CD4结合。IC50值:; 目标:艾滋病毒;NBD-556 N-苯基-Nα-(2,2,6,6-四甲基-哌啶-4-基)-草酰胺类似物是一类新型的人类免疫缺陷病毒1型(HIV-1)进入抑制剂,可阻断gp120 CD4相互作用。
警示图 | |
危险性 | warning |
危险性警示 | Acute Tox. 3 (100%) |
安全声明 | H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害 |
安全防护 | P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜(如果有)并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理 |
备注 | 实验过程中防止吸入、食入,做好安全防护 |
NBD-556(333353-44-9)危害标识:
象形图 | |
信号 | Danger |
GHS危险说明 | Aggregated GHS information provided by 39 companies from 1 notifications to the ECHA C&L Inventory. |
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral] | |
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. | |
防范说明代码 | P264, P270, P301+P310, P321, P330, P405, and P501 |
(The corresponding statement to each P-code can be found at the GHS Classification page.) |
Narumi, Tetsuo et al. CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorganic & Medicinal Chemistry Letters (2010), 20(19), 5853-5858. |
Schon A, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006 Sep 12;45(36):10973-10980. |
Singh IP, Chauthe SK. Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004-2010. Expert Opin Ther Pat. 2011 Mar;21(3):399-416. |
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology. 2005 Sep 1;339 |
Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study PMID 25001301; Antimicrobial agents and chemotherapy 2014 Sep; 58(9):5478-91 Name |
NBD-556(333353-44-9)参考文献:
1.Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
Liu T;Huang B;Zhan P;De Clercq E;Liu X Eur J Med Chem. 2014 Oct 30;86:481-90. doi: 10.1016/j.ejmech.2014.09.012. Epub 2014 Sep 6.
The HIV-1 entry into host cells is a complex, multi-factors involved, and multi-step process. Especially, the attachment of HIV-1 envelope glycoprotein gp120 to the host cell receptor CD4 is the first key step during entry process, representing a promising antiviral therapeutic target. Among the HIV-1 attachment inhibitors blocking the interaction between gp120 and CD4 cells, BMS-378806 and NBD-556 are two representative small molecular chemical entities. Particularly, BMS-378806 and its derivatives are newly identified class of orally bioavailable HIV-1 inhibitors that interfere gp120-CD4 interaction. In this review, we focused on describing the structure-activity relationships (SARs), structural modifications, in vitro or even in vivo pharmacodynamics and pharmacokinetics of BMS-378806 and its analogues as HIV-1 gp120 attachment inhibitors. In addition, the brief SARs, structural modifications of NBD-556 and its derivatives targeting the "Phe-43 cavity" as CD4 mimics were also described.
2.Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q;Ma L;Jiang S;Lu H;Liu S;He Y;Strick N;Neamati N;Debnath AK Virology. 2005 Sep 1;339(2):213-25.
We have identified two N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide analogs as a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitors that block the gp120-CD4 interaction, using database screening techniques. The lead compounds, NBD-556 and NBD-557, are small molecule organic compounds with drug-like properties. These compounds showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels. A systematic study showed that these compounds target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. These compounds were equally potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, respectively, indicating that their anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus. A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that these compounds bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4.
3.CD4-induced activation in a soluble HIV-1 Env trimer.
Guttman M;Garcia NK;Cupo A;Matsui T;Julien JP;Sanders RW;Wilson IA;Moore JP;Lee KK Structure. 2014 Jul 8;22(7):974-84. doi: 10.1016/j.str.2014.05.001. Epub 2014 Jun 12.
The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes. Env conformational changes have been observed using low-resolution electron microscopy, but only large-scale rearrangements have been visible. Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition. CD4 activation induces the reorganization of bridging sheet elements, V1/V2 and V3, much of the gp120 inner domain, and the gp41 fusion subunit. Two CD4 binding site-targeted inhibitors have substantially different effects: NBD-556 partially mimics CD4-induced destabilization of the V1/V2 and V3 crown, whereas BMS-806 only affects regions around the gp120/gp41 interface. The structural information presented here increases our knowledge of CD4- and small molecule-induced conformational changes in Env and the allosteric pathways that lead to membrane fusion.
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色,是通过细胞爬片是让玻片浸在细胞培养基内,细胞在玻片上生长,主要用于组织学,免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有:异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
各种微流控芯片键合方法的优缺点
微流控芯片键合:目前主要有激光焊接、热压键合、胶键合、超音波焊接,每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案:微流控芯片制造的一个重要环节,也是最容易被忽视的--芯片键合。其中一个重要因素是:微流控...
2023/7/27 12:44:28
荧光素钾盐使用说明
D-荧光素钾盐(K+)设计用于体外和体内生物发光测定。D-荧光素的质量和纯度对于获得良好和可重复的结果至关重...
2023/7/20 11:05:11
如何选BSA(牛血清白蛋白)
如何选BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多种形式,如何选择适合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18
牛血清白蛋白(BSA)常见问题
牛血清白蛋白(BSA)常见问题:牛血清白蛋白(BSA)在实验室中是通用的,可用于蛋白质印迹、细胞组织培养、P...
2022/10/19 9:39:51
pubmed使用方法(技巧)
pubmed使用方法(技巧):PubMed是一个关于医学问题的学术文章和书籍的数据库。因为它是一份学术期刊,...
2022/10/18 18:06:07
BSA(牛血清白蛋白)
BSA(牛血清白蛋白):牛血清白蛋白(BSA)是一种球状蛋白质,牛血清白蛋白(BSA)是发现于牛血浆中的主要...
2022/10/18 16:48:12
冻干培养细菌的方法
冻干培养细菌的方法:冷冻干燥,也称为冻干或冷冻干燥,是在产品冷冻后除去水分并将其置于真空中的过程。这使得冰可...
2022/10/16 8:27:31